On August 10, 2026, Agenus Inc.'s Compensation Committee approved a special one-time performance-based stock option award for Chairman and CEO Garo H. Armen. The award consists of 1,971,500 options with a $7.78 exercise price, set at the request of Dr. Armen to match other management grants and exceed the closing market price. Vesting is contingent on the stock price sustaining levels equal to 3x through 8x of the measurement price for 30 consecutive days within a five-year period, subject to a three-year minimum service requirement. Unvested options are forfeited upon termination without acceleration in a change of control. Agenus Inc. operates in the biotechnology industry, developing immunotherapies and vaccines.

On August 5, 2026, the board of directors of Agenus Inc. increased its size from six to seven members and appointed Marco Tullio Marcucci as a Class II director effective immediately. Mr. Marcucci will serve until the 2029 annual meeting and joined the Corporate Governance and Nominating Committee. He receives an annual cash retainer of $75,000 plus a $7,500 committee retainer and was granted an option to purchase 7,500 shares vesting over three years. Agenus Inc. operates in the biotechnology industry, focusing on cancer immunotherapy.

Agenus Inc. reported second-quarter 2026 financial results and announced the acceleration of its Phase 3 ROBBIN trial for neoadjuvant botensilimab plus balstilimab in microsatellite-stable colon cancer, with first patient dosing expected in Q1 2027. The company completed an oversubscribed $85 million private placement in July 2026, which includes warrants potentially providing up to $255 million more if fully exercised; these funds support operations through late 2031. Total revenue for the quarter was $34.5 million, including $6.4 million from pre-commercial product access programs and $28.1 million in non-cash royalty revenue. Agenus also discontinued funding for the BATTMAN Phase 3 trial following financing prioritization. Agenus Inc. is a clinical-stage immuno-oncology company developing antibody-based cancer immunotherapies.

Agenus Inc. entered into a Securities Purchase Agreement on July 13, 2026, for a private placement expected to close on July 15, 2026. The offering involves the issuance of 23,035,227 shares of common stock (or pre-funded warrants), along with Series A and Series B warrants, for expected aggregate gross proceeds of approximately $85 million. The company anticipates up to $255 million in additional gross proceeds upon full warrant exercise. Agenus will also expand its board of directors to nine members to include two individuals designated by Commodore Capital Master LP. Strategically, the company is prioritizing the development of its botensilimab and balstilimab combination for neoadjuvant treatment of MSS colon cancer via the Phase 3 ROBBIN trial, while discontinuing financial support for the BATTMAN Phase 3 study. Agenus is a biotechnology company developing immuno-oncology therapies.

Agenus Inc. entered into an amendment to its senior subordinated promissory notes and warrants on June 29, 2026. The company extended the maturity of $5.09 million in 2015 Notes to February 18, 2027, and extended the expiration dates of several existing warrants to June 25, 2031. Additionally, the company issued new 2026 D Warrants to purchase 56,525 shares of common stock at an exercise price of $3.25 per share. Agenus Inc. is a biotechnology company focused on developing immuno-oncology therapies.